- Welcome and Opening Remarks
- Overview of Asthma Pathophysiology and Role of Phenotypes
- Clinical Evidence on Treatment Recommendations
- Strategies for Patient Engagement, Quality Care, and Optimizing Treatment Outcomes
- Question and Answer
Suzanne G. Bollmeier, PharmD, FCCP, BCP, AE-C
St Louis College of Pharmacy
University of Health Sciences and Pharmacy
South County Health Center
St Louis, Missouri
Geoffrey C. Wall, PharmD, FCCP, BCPS
John R. Ellis Distinguished Chair of Pharmacy Practice
Professor of Clinical Sciences
Director, Drake Drug Information Center
Drake University College of Pharmacy and Health Sciences
Internal Medicine Clinical Pharmacist
Iowa Methodist Medical Center
Des Moines, Iowa
This program will provide expert-led guidance on the management of severe asthma incorporating the latest clinical guidelines and biologic therapies to individualize patient care and optimize patient outcomes.
The goal of this activity is to improve the knowledge and competence of pharmacists about severe asthma, including the latest clinical guidelines, current and emerging targeted biologic therapies for severe asthma, and strategies to improve patient-centered care.
The target audience for this activity is pharmacists, including managed care, specialty, and clinical pharmacists, who care for patients with severe asthma as well as pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice.
Upon completion of this activity, participants should be able to:
- Identify the underlying pathophysiology of moderate to severe asthma and corresponding targeted biologic therapies
- Discuss contemporary evidence regarding the efficacy, safety, and place in therapy for current and emerging targeted biologic therapies for severe asthma
- Integrate strategies to optimize patient-centered care, including managing healthcare costs, improving medication access, shared decision making, adherence to therapy, and collaborative care
ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-22-161-L01-P has been assigned to this live application-based activity (initial release date 5-18-2022). This activity is approved for 1.5 contact hours (0.15 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.
ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. Faculty disclosures will be provided prior to the start of the CE activity.